Evidence map›Paper›PMID 36288640›Full record

SynthesisJournal of infection and public health2022

An understanding of coronavirus and exploring the molecular dynamics simulations to find promising candidates against the Mpro of nCoV to combat the COVID-19: A systematic review.

Madhur Babu Singh, Ritika Sharma, Durgesh Kumar, Pankaj Khanna, Mansi, Leena Khanna, Vinod Kumar, Kamlesh Kumari, Akanksha Gupta, Preeti Chaudhary and 4 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Journal of infection and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Identification of Drug Targets and Their Inhibitors inPharmaceuticals (Basel, Switzerland) · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Madhur Babu SinghDepartment of Chemistry, Atma Ram Sanatan Dharma College, University of Delhi, New Delhi, India.
Ritika SharmaDepartment of Biochemistry, University of Delhi, New Delhi, India.
Durgesh KumarDepartment of Chemistry, Maitreyi College, University of Delhi, Delhi, India.
Pankaj KhannaDepartment of Chemistry, Acharya Narendra Dev College, University of Delhi, New Delhi, India.
MansiUniversity School of Basic and Applied Sciences, Guru Gobind Singh Indraprastha University, New Delhi, India.
Leena KhannaUniversity School of Basic and Applied Sciences, Guru Gobind Singh Indraprastha University, New Delhi, India.
Vinod KumarSpecial Centre for Nanoscience (SCNS), Jawaharlal Nehru University, New Delhi, India.
Kamlesh KumariDepartment of Zoology, University of Delhi, New Delhi, India.
Akanksha GuptaDepartment of Chemistry, Sri Venkateswara College, University of Delhi, New Delhi, India.
Preeti ChaudharyDepartment of Chemistry, Atma Ram Sanatan Dharma College, University of Delhi, New Delhi, India.
Neha KaushikDepartment of Biotechnology, College of Engineering, The University of Suwon, Hwaseong-si 18323, Republic of Korea. Electronic address: neha.bioplasma@gmail.com.
Eun Ha ChoiPlasma Bioscience Research Center, Department of Electrical and Biological Physics, Kwangwoon University, Seoul 01897, Republic of Korea.
Nagendra Kumar KaushikPlasma Bioscience Research Center, Department of Electrical and Biological Physics, Kwangwoon University, Seoul 01897, Republic of Korea. Electronic address: kaushik.nagendra@kw.ac.kr.
Prashant SinghDepartment of Chemistry, Atma Ram Sanatan Dharma College, University of Delhi, New Delhi, India. Electronic address: psingh@arsd.du.ac.in.
University of Delhi · INGuru Gobind Singh Indraprastha University · INKwangwoon University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first infection case of new coronavirus was reported at the end of 2019 and after then, the cases are reported in all nations across the world in a very short period. Further, the regular news of mutations in the virus has made life restricted with appropriate behavior. To date, a new strain (Omicron and its new subvariant Omicron XE) has brought fear amongst us due to a higher trajectory of increase in the number of cases. The researchers thus started giving attention to this viral infection and discovering drug-like candidates to cure the infections. Finding a drug for any viral infection is not an easy task and takes plenty of time. Therefore, computational chemistry/bioinformatics is followed to get promising molecules against viral infection. Molecular dynamics (MD) simulations are being explored to get drug candidates in a short period. The molecules are screened via molecular docking, which provides preliminary information which can be further verified by molecular dynamics (MD) simulations. To understand the change in structure, MD simulations generated several trajectories such as root mean square deviation (RMSD), root mean square fluctuation (RMSF), hydrogen bonding, and radius of gyration for the main protease (Mpro) of the new coronavirus (nCoV) in the presence of small molecules. Additionally, change in free energy for the formation of complex of Mpro of nCoV with the small molecule can be determined by applying molecular mechanics with generalized born and surface area solvation (MM-GBSA). Thus, the promising molecules can be further explored for clinical trials to combat coronavirus disease-19 (COVID-19).

Indexed as

Coronavirus 3C ProteasesCOVID-19Drug DiscoveryComputational BiologyCOVID-19 Drug TreatmentHumansMolecular Docking SimulationMolecular Dynamics SimulationCoronavirus 3C ProteasesMolecular dynamics simulationsMpro of nCoVPromising drug like candidateSARS-CoV-2

Identifiers

PMID36288640
PMCPMC9579205
OpenAlexW4306777600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.